TY - JOUR
T1 - Transpapillary iontophoretic delivery of resveratrol loaded transfersomes for localized delivery to breast cancer
AU - Gadag, Shivaprasad
AU - Narayan, Reema
AU - Sabhahit, Jayalakshmi N.
AU - Hari, Gangadhar
AU - Nayak, Yogendra
AU - Pai, Karkala Sreedhara Ranganath
AU - Garg, Sanjay
AU - Nayak, Usha Y.
N1 - Funding Information:
This project was supported by the Science and Engineering Research Board , Department of Science and Technology , New Delhi, India ( EMR/2016/007006 ).
Publisher Copyright:
© 2022
PY - 2022/9
Y1 - 2022/9
N2 - Localized drug delivery to the breast tissues is an area of interest as a potential route to ensure site-specific drug delivery. Transpapillary delivery via the mammary papilla has advantages as most breast tumors arise from the milk ducts. The present study explored the plausibility of transpapillary delivery of a phytochemical, resveratrol (RVT), for breast cancer treatment. RVT was encapsulated within the transfersomes (RVT-TRF) to enable a sustained release of the drug using the biomaterial soya phosphatidylcholine (SPC). Iontophoresis was applied to further accelerate the penetration of the RVT-TRF across the mammary papilla to the breast tissue. The RVT-TRF development was optimized by the Design of Experiments (DoE) approach. The in vitro transpapillary iontophoresis study on porcine mammary papilla showed an enhanced penetration of RVT-TRF when compared to passive diffusion. The transpapillary delivery was further confirmed from the in vitro fluorescent microscopy study using FITC conjugated RVT-TRF. The optimized RVT-TRF delivered via transpapillary route showed a higher Cmax and AUC when compared to pure RVT given orally. A significant reduction in the tumor volume and the serum biomarker CA 15-3, when evaluated in a chemically induced breast cancer rat model, provided evidence of the effectiveness of the developed formulation when delivered locally via transpapillary route compared to the oral route. Thus the developed RVT-TRF administered via transpapillary iontophoresis technique is a promising strategy enabling a localized delivery for effective breast cancer therapy.
AB - Localized drug delivery to the breast tissues is an area of interest as a potential route to ensure site-specific drug delivery. Transpapillary delivery via the mammary papilla has advantages as most breast tumors arise from the milk ducts. The present study explored the plausibility of transpapillary delivery of a phytochemical, resveratrol (RVT), for breast cancer treatment. RVT was encapsulated within the transfersomes (RVT-TRF) to enable a sustained release of the drug using the biomaterial soya phosphatidylcholine (SPC). Iontophoresis was applied to further accelerate the penetration of the RVT-TRF across the mammary papilla to the breast tissue. The RVT-TRF development was optimized by the Design of Experiments (DoE) approach. The in vitro transpapillary iontophoresis study on porcine mammary papilla showed an enhanced penetration of RVT-TRF when compared to passive diffusion. The transpapillary delivery was further confirmed from the in vitro fluorescent microscopy study using FITC conjugated RVT-TRF. The optimized RVT-TRF delivered via transpapillary route showed a higher Cmax and AUC when compared to pure RVT given orally. A significant reduction in the tumor volume and the serum biomarker CA 15-3, when evaluated in a chemically induced breast cancer rat model, provided evidence of the effectiveness of the developed formulation when delivered locally via transpapillary route compared to the oral route. Thus the developed RVT-TRF administered via transpapillary iontophoresis technique is a promising strategy enabling a localized delivery for effective breast cancer therapy.
UR - http://www.scopus.com/inward/record.url?scp=85136556851&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85136556851&partnerID=8YFLogxK
U2 - 10.1016/j.bioadv.2022.213085
DO - 10.1016/j.bioadv.2022.213085
M3 - Article
AN - SCOPUS:85136556851
SN - 2772-9508
VL - 140
JO - Biomaterials Advances
JF - Biomaterials Advances
M1 - 213085
ER -